Anti-SPRY2 Rabbit Polyclonal Antibody for WB, IHC-P, ELISA - O43597

Core Product Specifications and Parameters

Biological Background: SPRY2 Function and Localization

• Protein sprouty homolog 2 (SPRY2) is a member of the sprouty family that antagonizes receptor tyrosine kinase signaling, particularly the fibroblast growth factor (FGF) pathway.
• SPRY2 inhibits FGF-mediated phosphorylation of ERK1/2, thereby acting as a negative regulator of FGF-induced retinal lens fiber differentiation, limb bud outgrowth, and respiratory organogenesis (By similarity).
• It also inhibits transforming growth factor beta (TGFB)-induced epithelial-to-mesenchymal transition in retinal lens epithelial cells (By similarity).
• SPRY2 inhibits CBL/C-CBL-mediated EGFR ubiquitination, affecting receptor downregulation. Related references: PMID:17974561
• Subcellularly, SPRY2 localizes to the cytoplasm, cytoskeleton, cell projections, and ruffle membranes, indicating roles in cell dynamics and signaling.
• The protein is associated with developmental processes and has been implicated in disease variants (UniProt keyword: Disease variant).
• Its molecular weight is approximately 35 kDa (UniProt: 34,688 Da).

Experimental Guidance and Technical Tips

• The immunogen is a synthetic peptide corresponding to the N-terminal region (amino acids 1–100) of human SPRY2, which may detect the full-length protein and potential isoforms.
• For Western blotting, a band around 35 kDa is expected; validate in relevant human or mouse cell or tissue lysates.
• The antibody has been reported for use in immunohistochemistry (paraffin-embedded sections); consider appropriate antigen retrieval and detection methods.
• As a polyclonal antibody, lot-to-lot consistency should be verified for critical quantitative assays.
• For ELISA, pairing with a capture antibody or direct detection may be optimized based on the specific assay format.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio provides diagnostic manufacturers and researchers with streamlined access to validated antibodies and ancillary reagents for key signaling targets like SPRY2. Our portfolio includes optimized monoclonal and polyclonal antibodies, bulk reagents, and support for rare-target sourcing to accelerate assay development from concept to clinic.